| Objective To investigate the therapeutic effects of rosiglitazone on the level of serum glucagon-like peptide-1(GLP-1).Methods Totally seventy-four patients aged 38-75 years of Type 2 diabetic who need to use insulin and metformin therpy were selected. The body mass index (BMI) was 21.5-29.5kg/m2, and the average BMI was 25.5±2.4kg/m2. Except for severe cardiac insufficiency, liver and kidney dysfunctionand.The patients who were allergy with thiazolidinediones (TZDS). They were not have other major diseases such as hypertension and coronary heart disease. Except for pregnant women and breastfeeding women and not have acute conplications, not participate in clinical trials by other drug in three months. They were random divided into two groups.38 patients as study group took use of insulin and together with rosiglitazone (4 mg/day)orally for 6 months.36 other patients were as control group. To examine the limosis serum glucagon-like peptide-1 (GLP-1) by using the Enzyme-Linked-Immunosorbent Assay (ELISA), to examine the limosis,2h postprandial blood glucose and blood lipid by using oxidase method, to examine the glycated hemoglobin by using column chromatography and to examine the limosis insulin by using Chemiluminescence. The changes of blood glucose, insulin, HbAlc, GLP-1 were observed before and after treatment. All statistical tests were carried out using the SPSS 1.0-program. Measurement data interclass was indicated with x±s.The comparison between groups were tested using t test.Results There were no differences in the age,yeas of diabetes mellitus,body mass index and gender between the two groups (P>0.05). In the a group, FPG,2hFG, HbAlc, FINS, TC, and TG decreased significantly after 6-month treatment (P<0.05), a group showed an increased GLP-1 secretion compared with b group(P<0.05).Conclusions Rosiglitazone can effectively control blood glucose and HbAlc, lower the insulin resistance, and increase serum levels of GLP-1 in patients with type 2 diabetes. |
PDF Full Text Request